Roche appeals, fights for new Accutane judge 
Published: March 11, 2013
Tags: Accutane, birth defects, DRI, drug litigation, Hoffmann-La Roche, inflammatory bowel disease, recusal
Continuing in its efforts to find a new judge for the thousands of Accutane cases pending in New Jersey state court, Hoffman-La Roche filed notice to appeal a decision by presiding Judge Carol E. Higbee not to recuse herself in the case.
N.J. judge refuses to recuse herself from Accutane cases
Published: March 4, 2013
Tags: Accutane, birth defects, DRI, drug litigation, Hoffmann-La Roche, inflammatory bowel disease, recusal, suicide
The state judge overseeing Accutane mass tort litigation in New Jersey has denied Hoffmann- La Roche’s motion asking that she recuse herself.
Hoffmann-La Roche asks for Accutane judge’s recusal
Published: December 28, 2012
Tags: Accutane, drug litigation, Hoffmann-La Roche, inflammatory bowel disease, mass tort litigation, recusal
Drug maker Hoffmann- La Roche has asked for the recusal of the New Jersey judge overseeing the Accutane mass tort litigation, asserting that Judge Carol E. Higbee is siding unfairly with plaintiffs who allege injuries from the acne drug.
Accutane warning ruled adequate
Published: August 2, 2012
Tags: Accutane, Hoffmann-La Roche, inflammatory bowel disease, product liability
Pharmaceutical company Hoffmann-La Roche adequately warned a user of the acne drug Accutane of the risk of developing inflammatory bowel disease, a U.S. District Court in Florida has ruled in granting summary judgment.
New Jersey court upholds $25 million Accutane verdict
Published: September 28, 2011
Tags: Accutane, IBD, inflammatory bowel disease
Denying a defense motion for remittitur or new trial, a New Jersey judge has affirmed a jury’s $25.16 million award to an Alabama man who suffered from inflammatory bowel disease as a result of taking the acne medication Accutane.
Accutane verdicts: $2 million for one plaintiff out of three
By:
Correy Stephenson
Published: April 22, 2011
Tags: Accutane, Crohn’s disease, drug litigation, failure to warn, Hoffman-LaRoche, IBD, inflammatory bowel disease
In a trio of cases tried together against Hoffman-LaRoche, the maker of Accutane, jurors awarded just one of the plaintiffs suffering from inflammatory bowel disease $2.1 million.
$10.5 million Accutane verdict reversed
By:
Correy Stephenson
Published: August 10, 2010
Tags: Accutane, inflammatory bowel disease, product liability
A trial judge improperly limited the defense’s evidence regarding the overall number of Accutane users, the New Jersey Appellate Division has ruled in reversing a $10.5 million verdict for the plaintiff.
N.J. jury awards $25 million to Accutane user with IBD
By:
Nora Tooher
Published: February 25, 2010
Tags: Accutane, inflammatory bowel disease, Roche Laboratories
In a retrial, a New Jersey jury has awarded $25.16 million – nearly 10 times the original award – to an Alabama man with inflammatory bowel disease.
